Results 211 to 220 of about 2,555,654 (307)

Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia. [PDF]

Int J Lab Hematol
Mishra S, Kumar K, Kumar D, Kamak A, Singh L, Kumar N.   +5 more
europepmc   +1 more source

Is there a best frontline therapy in chronic myeloid leukemia? [PDF]

Haematologica
Jain AG, Dalgetty M, Cortes JE.
europepmc   +1 more source

Cytogenetic Diversity of Variant Philadelphia Translocations in Chronic Myeloid Leukemia. [PDF]

Int J Lab Hematol
Tokac AGB, Aday A, Erdem S, Bagatir G, Don B, Ozcan O, Yavuz AS, Besisik SK, Nalcaci M, Cefle K, Ozturk S.   +10 more
europepmc   +1 more source

Spontaneous splenic rupture as the first manifestation of chronic myeloid leukemia: A case report. [PDF]

Qatar Med J
Rustom A, Ibrahim Z, Alahmad Y, Jamil O, Mahgoub R, Mirza S.   +5 more
europepmc   +1 more source

Phagocytosis activity is retained by JMML macrophages and increased by CD47 inhibition

British Journal of Haematology, EarlyView.
Summary Juvenile myelomonocytic leukaemia (JMML) is a childhood myeloid malignancy driven by RAS (rat sarcoma viral oncogene homolog) pathway mutations, characterized by myeloid cell accumulation and organ infiltration. We investigated how clonal macrophage polarization, phagocytic function and CD47 (cluster of differentiation 47) expression contribute
Jun Wang, Jovana Rajak, Hui Xiao, Naile Koleci, Anna Lena Stippel, Ke Meng, Niels Anton Wehner, Sheila Bohler, Riccardo Masetti, Charlotte Niemeyer, Bertram Bengsch, Miriam Erlacher   +11 more
wiley   +1 more source

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

British Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper, Michal Kicinski, Tobias Ma, Thomas Meyer, Sylvain Chantepie, Richard Noppeney, Mario Luppi, Ernesta Audisio, Laimonas Griškevičius, Andreas Neubauer, Robin Foà, Walter J. F. M. Van der Velden, Anna Candoni, Radovan Vrhovac, Gianluca Gaidano, Catharina Van Elssen, Mels Hoogendoorn, Maurizio Musso, Attilio Olivieri, Christian Junghanß, Emmanuel Bissé, Stephanie Antunes, Frédéric Baron, Adriano Venditti, Joop H. Jansen, Pierre W. Wijermans, Gerwin Huls, Michael Lübbert   +27 more
wiley   +1 more source

Therapeutic drug monitoring guides personalized ponatinib dose reduction for chronic myeloid leukemia. [PDF]

Int J Hematol
Abumiya M, Takahashi N.
europepmc   +1 more source

Algorithms in Allergy: Treatment of Hypereosinophilic Syndromes, 2026 Update

Allergy, EarlyView.
Guillaume Lefèvre, Florence Roufosse, Giacomo Emmi, Andreas Reiter, Emmanuel Ledoult, Jean‐Emmanuel Kahn   +5 more
wiley   +1 more source